AEterna Zentaris Inc.  

(Public, TSE:AEZ)   Watch this stock  
Find more results for AEZ
4.40
-0.13 (-2.87%)
Jul 25 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 4.38 - 4.55
52 week 3.77 - 29.00
Open 4.51
Vol / Avg. 9,460.00/15,030.00
Mkt cap 43.49M
P/E     -
Div/yield     -
EPS -29.17
Shares 9.94M
Beta 1.37
Inst. own     -
Aug 10, 2016
Q2 2016 AEterna Zentaris Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 10, 2016
Q1 2016 AEterna Zentaris Inc Earnings Call
May 9, 2016
Q1 2016 AEterna Zentaris Inc Earnings Release
  

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -1519.01% -9216.15%
Operating margin -2888.84% -6400.73%
EBITD margin - -6338.16%
Return on average assets -30.86% -101.54%
Return on average equity -77.78% -278.28%
Employees 46 -
CDP Score - -

Address

1 Ville-Marie Pl Suite 2500
MONTREAL, QC H3B 1R1
Canada
+1-514-8474516 (Phone)
+1-418-9489191 (Fax)

Website links

Description

Aeterna Zentaris Inc. is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The Company's principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Company focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The Company's direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc.

Officers and directors

David A. Dodd Chairman of the Board, President, Chief Executive Officer
Age: 65
Dennis Turpin CA Chief Financial Officer, Senior Vice President
Philip Allen Theodore Senior Vice President, Chief Administrative Officer, General Counsel
Age: 62
Richard Sachse M.D. Ph.D. Senior Vice President, Chief Scientific Officer, Chief Medical Officer
Jude Dinges Chief Commercial Officer, Senior Vice President
Genevieve Lemaire Chief Accounting Officer, Vice President - Finance
Michael Teifel Vice President - Non-Clinical Sciences
Juergen H. L. Ernst Lead Independent Director
Age: 76
Michael A. Cardiff Director
Kenneth E. Newport CPA Director
Age: 49